Alzheimer's Disease Diagnostics And Therapeutics Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 7.70 Billion |
| Market Size (2029) | USD 10.10 Billion |
| CAGR (2024 - 2029) | 5.57 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Alzheimer's Disease Diagnostics And Therapeutics Market Analysis
The Alzheimer's Disease Diagnostics And Therapeutics Market size is estimated at USD 7.70 billion in 2024, and is expected to reach USD 10.10 billion by 2029, growing at a CAGR of 5.57% during the forecast period (2024-2029).
The major factors driving the growth of the Alzheimer's disease diagnostics and therapeutics market are the increasing use of biomarkers in Alzheimer's diagnosis and drug development and the rising prevalence of Alzheimer's worldwide. For instance, in September 2023, a report by the WHO stated that about 55 million people around the world are living with dementia, and nearly 10 million cases are reported annually. WHO also said that Alzheimer's is the most common form of dementia and constitutes about 60%-70% of the total cases of dementia.
Also, with the growing prevalence of Alzheimer's around the world, government and non-government entities are investing heavily in developing diagnostics and therapeutics for the disease, which may augment the market's growth. For instance, as per the NIH in May 2022, the funding for research and development of Alzheimer’s Disease in 2021 is estimated to be USD 3,059 million, which rises to USD 3,348 million in 2022. This shows the increased research funding for the diseases, which likely increases the usage of the diagnostics and treatment options that drive the market over the forecast period.
Additionally, with the advancement in diagnostic technologies and ongoing research activities in the area, the companies are enhancing their product offering and launching new products coupled with other business expansion initiatives like mergers and acquisitions, strategic collaboration, and new investments into other companies are also expected to complement the growth of the Alzheimer's disease diagnostics and therapeutics market over the forecast period. For instance, in February 2023, Athira Pharmaceuticals released its list of planned clinical trials for 2023, which included the development of therapeutic drugs for the treatment of Alzheimer’s disease. In January 2023, Cyclo Therapeutics, Inc. announced that the first patient had been enrolled and dosed in its phase IIb study of Trappsol Cyclo for treating early Alzheimer’s disease (AD). It targets the disrupted lipid pathways and the reduction of amyloid beta and tau. Thus, such therapeutics development leads to better drugs for Alzheimer's treatments, thereby driving the growth of the studied market.
Thus, the studied market is expected to witness healthy growth over the forecast period due to the use of biomarkers, increasing research and development, and advanced diagnostic technologies. However, high failure rates of clinical studies related to diagnosis and treatment and challenges in early diagnostics of Alzheimer's may impede the market growth over the forecast period.
Alzheimer's Disease Diagnostics And Therapeutics Market Trends
Cholinesterase Inhibitors is Expected to Witness a Significant Growth Over the Forecast Period.
Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, are a class of therapeutics that stop the normal breakdown of acetylcholine, a neurotransmitter. The cholinesterase inhibitors shut off the action of the enzyme cholinesterase, which is responsible for breaking down acetylcholine neurotransmitters in the body. As cholinesterase inhibitors are found to slightly delay the loss of brain function in people suffering from mild to moderate focus Alzheimers disease, they are widely prescribed to treat symptoms related to memory, thinking, language, judgment, and other thought processes. Currently, the major cholinesterase inhibitor drugs available for Alzheimer's use in the market are donepezil, galantamine, rivastigmine, and memantine.
Currently, in the market, cholinesterase inhibitors are the drugs available for Alzheimer's because the enzyme cholinesterase is a significant therapeutic primary for Alzheimer's. Hence, the segment is expected to grow over the forecast period as several pharmaceutical companies Alzheimer's develop Alzheimer's therapeutics based on cholinesterase inhibitors. For instance, in February 2023, Merck Sharp & Dohme LLC conducted a study, Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007), which is in phase I stage.
Also, a recent study published in March 2022, led by Karolinska Institute researchers in Sweden, demonstrated continued cognitive advantages and decreased mortality for up to five years following diagnosis. The findings demonstrated that cholinesterase inhibitor therapy was related to slower cognitive deterioration over five years and 27% decreased mortality in Alzheimer's disease patients compared with controls.
Thus, due to the practical results of cholinesterase inhibitors in treating Alzheimer's disease, new product launches and the increasing geriatric population are expected to witness significant growth over the forecast period.
North America is Expected to Witness a Significant Growth Over the Forecast Period.
North America is expected to witness significant growth over the forecast period owing to the high burden of Alzheimer's disease and the increasing aging population, huge investment in research and development activities, and the launch of new products in the region.
In February 2023, Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc. Cerveau’s asset is MK-6240, a second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease. In January 2023, Otsuka and Lundbeck stated that the Food and Drug Administration (FDA) accepted and assigned the application priority review of sNDA for aripiprazole to treat agitation associated with Alzheimer’s dementia. Hence, such company activities and government support are expected to increase the market over the forecast period.
Also, the growing aging population in the region is expected to increase the burden of Alzheimer's disease, as the geriatric population is more prone to neurodegenerative diseases like Alzheimer's as it is an age-associated disease. For instance, in March 2022, the Alzheimer's Association Report stated that approximately 6.2 million people aged 65 years and more are living with Alzheimer 's-related dementia in the United States, and it is projected that this number will increase to 13.8 million people by 2060.
With the increasing number of research studies related to the diagnosis and management of Alzheimer's disease and high investment in the country over Alzheimer's by the government and private entities, the market is expected to grow in the United States over the forecast period. For instance, as per the NIH in May 2022, the funding for research and development of Alzheimer’s Disease in 2021 is estimated to be USD 3,059 million, which rises to USD 3,348 million in 2022
Therefore, due to the high burden of Alzheimer's disease and huge investment in research and development activities, coupled with the launch of new products, the Alzheimer's disease diagnostics and therapeutics market is expected to grow over the forecast period in the region
Alzheimer's Disease Diagnostics And Therapeutics Industry Overview
The Alzheimer's disease diagnostics and therapeutics market is moderately competitive and consists of several significant players; some of the companies are F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Corium Inc., Eisai Co. Ltd, Biogen Inc., Johnson & Johnson, Eli Lilly and Company, Lupin Limited, AbbVie Inc., Siemens Healthineers, Zydus Cadila, Merz Pharma, Teva Pharmaceutical Industries Ltd, and Adamas Pharmaceuticals Inc.
Alzheimer's Disease Diagnostics And Therapeutics Market Leaders
-
F. Hoffmann-La Roche
-
Bristol-Myers Squibb
-
AstraZeneca PLC
-
Johnson & Johnson
-
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
Alzheimer's Disease Diagnostics And Therapeutics Market News
• In January 2024, Eisai Co. Ltd received approval for its humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody LEQEMBI in China for the treatment of patients with Alzheimer’s disease.
• In December 2023, AbbVie Inc. signed an agreement to acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases, including schizophrenia, Parkinson's disease (PD), and mood disorders. This acquisition will include Emraclidine, a positive allosteric modulator (PAM) of the muscarinic M4 receptor, which is currently in a Phase 1 study in elderly healthy volunteers in support of a potential Alzheimer's disease psychosis program.
Alzheimer's Disease Diagnostics And Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Use of Biomarkers in Diagnosis and Drug Development
- 4.2.2 Large Number of Drugs in Pipeline
- 4.2.3 Emerging Novel Diagnostic Technologies
-
4.3 Market Restraints
- 4.3.1 High Failure Rates of Late-stage Drugs
- 4.3.2 Lack of Surrogate Markers and Challenges in Early Diagnosis
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 Product
- 5.1.1 Therapeutics
- 5.1.1.1 Cholinesterase Inhibitors
- 5.1.1.2 NMDA Receptor Antagonists
- 5.1.1.3 Other Therapeutics
- 5.1.2 Diagnostics
- 5.1.2.1 Brain Imaging
- 5.1.2.2 CFS Test for Alzheimer's Disease
- 5.1.2.3 Other Diagnostics
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kingdom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Middle East and Africa
- 5.2.4.1 GCC
- 5.2.4.2 South Africa
- 5.2.4.3 Rest of Middle East and Africa
- 5.2.5 South America
- 5.2.5.1 Brazil
- 5.2.5.2 Argentina
- 5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 F. Hoffmann-La Roche
- 6.1.2 Bristol-myers Squibb Company
- 6.1.3 AstraZeneca PLC
- 6.1.4 Corium Inc.
- 6.1.5 Eisai Co. Ltd
- 6.1.6 Biogen Inc.
- 6.1.7 Johnson & Johnson
- 6.1.8 Eli Lilly and Company
- 6.1.9 Lupin Limited
- 6.1.10 AbbVie Inc.
- 6.1.11 Siemens Healthineers
- 6.1.12 Zydus Group (zydus Lifesciences Limited)
- 6.1.13 Merz Pharma
- 6.1.14 Teva Pharmaceutical Industries Ltd
- 6.1.15 Novartis AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Alzheimer's Disease Diagnostics And Therapeutics Industry Segmentation
Alzheimer's disease is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss of memory, thinking and language skills, and behavioral changes. There is a rapid growth in the number of people living with Alzheimer's disease, and only around one in four people with the disease get diagnosed. The Alzheimer's Disease Diagnostics and Therapeutics Market is Segmented by Product, which is sub-segmented as Therapeutics -Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Other Therapeutics and Diagnostics - Brain Imaging and CSF Test and Other Diagnostics for Alzheimer's Disease. The market is geographically segmented as North America, Europe, Asia-Pacific, the Middle East, Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across the major regions globally. The report offers the value (in USD ) for all the above segments.
| Product | Therapeutics | Cholinesterase Inhibitors |
| NMDA Receptor Antagonists | ||
| Other Therapeutics | ||
| Product | Diagnostics | Brain Imaging |
| CFS Test for Alzheimer's Disease | ||
| Other Diagnostics | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Alzheimer's Disease Diagnostics And Therapeutics Market Research FAQs
How big is the Alzheimer's Disease Diagnostics And Therapeutics Market?
The Alzheimer's Disease Diagnostics And Therapeutics Market size is expected to reach USD 7.70 billion in 2024 and grow at a CAGR of 5.57% to reach USD 10.10 billion by 2029.
What is the current Alzheimer's Disease Diagnostics And Therapeutics Market size?
In 2024, the Alzheimer's Disease Diagnostics And Therapeutics Market size is expected to reach USD 7.70 billion.
Who are the key players in Alzheimer's Disease Diagnostics And Therapeutics Market?
F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Johnson & Johnson and Eli Lilly and Company are the major companies operating in the Alzheimer's Disease Diagnostics And Therapeutics Market.
Which is the fastest growing region in Alzheimer's Disease Diagnostics And Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Alzheimer's Disease Diagnostics And Therapeutics Market?
In 2024, the North America accounts for the largest market share in Alzheimer's Disease Diagnostics And Therapeutics Market.
What years does this Alzheimer's Disease Diagnostics And Therapeutics Market cover, and what was the market size in 2023?
In 2023, the Alzheimer's Disease Diagnostics And Therapeutics Market size was estimated at USD 7.27 billion. The report covers the Alzheimer's Disease Diagnostics And Therapeutics Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Alzheimer's Disease Diagnostics And Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Alzheimer's Disease Diagnostics And Therapeutics Industry Report
Statistics for the 2024 Alzheimer's Disease Diagnostics and Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Alzheimer's Disease Diagnostics and Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
